Targeted Protein Degradation Systems with Integrated AI, IoT, and Blockchain Technologies
Legal Citation
Summary of the Inventive Concept
This inventive concept integrates compounds for targeted protein degradation with AI, IoT, and blockchain technologies to create a more powerful and personalized system for treating diseases such as cancer.
Background and Problem Solved
The original patent disclosed compounds and methods for targeted degradation of enhancer of zeste homolog 2 polypeptide. However, these compounds have limited efficacy and specificity. The new inventive concept addresses these limitations by combining the compounds with AI-driven analysis, IoT-enabled sensors, and blockchain-secured payloads to create a more effective and personalized system.
Detailed Description of the Inventive Concept
The inventive concept consists of a compound having the chemical structure ULM-L-PTM, which binds to an E3 ubiquitin ligase and a target protein, respectively. The compound is integrated with a machine learning module that predicts optimal ubiquitin ligase-target protein combinations. The system also includes a blockchain-secured payload and IoT-enabled sensors for monitoring the subject's response. Additionally, the system may utilize AI-driven simulations to design novel materials with enhanced bioavailability.
Novelty and Inventive Step
The new inventive concept combines the compounds of the original patent with AI, IoT, and blockchain technologies, which is not obvious from the original patent. The integration of these technologies provides a synergistic effect, resulting in a more effective and personalized system.
Alternative Embodiments and Variations
Alternative embodiments may include using different AI algorithms, IoT-enabled devices, or blockchain platforms. The system may also be adapted for use in various diseases or conditions, such as neurodegenerative disorders or infectious diseases.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, particularly in the development of personalized medicines for cancer and other diseases. The integration of AI, IoT, and blockchain technologies also opens up opportunities for partnerships and collaborations with companies in these fields.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K31/166 |
| A | A61 | A61K31/351 |
| A | A61 | A61K31/405 |
| A | A61 | A61K38/45 |
| A | A61 | A61K47/545 |
| A | A61 | A61K47/55 |
| A | A61 | A61K47/555 |
| A | A61 | A61P35/00 |
| C | C07 | C07D401/14 |
| C | C07 | C07D405/12 |
| C | C07 | C07D405/14 |
| C | C07 | C07D409/14 |
| C | C07 | C07D417/14 |
| C | C07 | C07D471/04 |
| C | C12 | C12N9/1007 |
| C | C12 | C12Y201/01043 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Medicinal Chemistry, Pharmaceutical Biotechnology, and Targeted Protein Degradation with emphasis on computational drug design and personalized medicine technologies
Person of Ordinary Skill (PHOSITA) Profile
A researcher with advanced degrees in chemistry or pharmaceutical sciences, expertise in protein engineering, computational biology, and familiarity with emerging technologies like AI, blockchain, and IoT in medical applications
Obviousness Rationale
A PHOSITA would recognize that integrating computational technologies with targeted protein degradation compounds represents a natural progression of drug development strategies. The combination of AI-driven analysis, IoT monitoring, and blockchain security with existing protein degradation compounds provides a predictable and incremental improvement in personalized medicine approaches. The technical elements disclosed in the PTD represent logical extensions of known methodologies in drug design and precision medicine.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,519 |
|---|---|
| Title | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| Assignee(s) | Arvinas Operations, Inc. |